SP1 and myocardial infarction: Angiotensin II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) remarkably prevent Sp1 DNA binding activity in the infarcted area post MI36, suggesting that miR-7a/b may act similarly to these drugs and may be potentially suitable as an intervention in MI.